Journal September 25, 2026 7 min read

Common Misconceptions About Resting Metabolic Rate

Resting metabolic rate (RMR) is the energy expended by an organism at rest in a thermoneutral environment, measured after an overnight fast and before physical activity. This page examines common misconceptions about RMR

peptides-pro Editorial

What Is Resting Metabolic Rate?

Resting metabolic rate (RMR) is the rate of energy expenditure by an organism under resting, postabsorptive, thermoneutral conditions. It is often used interchangeably with resting energy expenditure (REE), though RMR is typically measured under slightly less stringent conditions than basal metabolic rate (BMR). RMR accounts for the majority of daily energy expenditure in most individuals and is influenced by body composition, particularly fat-free mass, as well as age, sex, and hormonal status. The evidence block does not provide a molecular formula, sequence, or identifier for RMR itself, as it is a physiological measurement rather than a discrete compound.

The work described in the evidence centres on metabolic pathways and receptor families including glucagon-like peptide-1 receptor (GLP-1R) agonists, activin type II receptor (ActRII) inhibitors, and sirtuin (SIRT) family proteins, particularly SIRT1 and SIRT3 [3][4].

Research Studies

HMB and Vitamin D3 in Older Adults Starting Semaglutide

A randomized, double-blind, placebo-controlled trial is evaluating whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care [1]. Participants receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6. Secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, and resting metabolic rate [1]. This study addresses the misconception that RMR decline during weight loss is unavoidable; it tests whether a nutritional intervention can preserve resting metabolism in a population starting a GLP-1 receptor agonist.

Tirzepatide and Bimagrumab on Body Composition and Resting Metabolic Rate

In adults with obesity seeking treatment, weight loss would ideally be composed almost exclusively of fat mass. However, loss of muscle mass and bone are unintentional consequences of weight loss, which may have negative effects on health by lessening improvements in glucose and insulin levels, reducing resting metabolic rate, and increasing the risk of falls and fractures [4]. Data in animals and humans suggest that bimagrumab, an investigational new drug for obesity that inhibits the activin type II receptor (ActRII) inhibitor, may help maximize loss of fat mass while maintaining muscle mass when used in combination with a glucagon-like peptide 1 receptor agonist (GLP-1 RA) [4]. This study challenges the misconception that RMR reduction is solely determined by fat loss; it examines whether preserving muscle mass through ActRII inhibition can mitigate RMR decline.

Metabolic Phenotyping for Personalized Obesity Therapy

A prospective, single-center, longitudinal study aims to develop a simple, clinically applicable method for metabolic phenotyping to personalize obesity therapy in morbidly obese individuals [8]. The underlying concept is that the way a person's resting metabolic rate (RMR) responds to a 24-hour fast can help distinguish between two metabolic phenotypes. Individuals with a "thrifty" metabolism show a significant drop in RMR during fasting, which may make them less responsive to conventional weight loss interventions. In contrast, those with a "spendthrift" metabolism exhibit little to no drop—or even a slight increase—in RMR, suggesting they may lose weight more readily [8]. This study addresses the misconception that RMR is a static trait; it investigates whether RMR adaptability during fasting can predict weight loss response.

Sirtuin Activators and Weight Loss

Obesity is a chronic, multifactorial disease associated with a high burden of metabolic, cardiovascular, and psychosocial complications. Despite extensive research, the long-term effectiveness of lifestyle-based weight-management strategies remains limited, and there is a growing interest in molecular pathways that may enhance metabolic flexibility and improve treatment outcomes [3]. Among these pathways, the sirtuin (SIRT) family—particularly SIRT1 and SIRT3—has emerged as a promising target due to its involvement in mitochondrial biogenesis, energy expenditure, oxidative metabolism, and the regulation of insulin sensitivity. Bioactive compounds that activate sirtuins, including nicotinamide riboside, are being studied for their potential to influence RMR [3]. This research challenges the misconception that RMR is fixed and cannot be modulated by molecular interventions.

Energy Deficiency and Athletic Performance

Energy availability (EA) refers to the balance between daily energy intake and exercise energy expenditure. Athletically inadequate EA is defined as low energy availability (LEA). Energy deficits occur throughout life, from young athletes with a relative lack of energy in sports or the female athlete triad to older adults struggling with weight loss. Acute and/or chronic LEA can cause negative athletic and health outcomes in athletes [7]. It is known that LEA, as an energy saving mechanism, suppresses the reproductive system and causes disruption of the menstrual cycle, as well as causing many interrelated endocrine-related physiological consequences by changing other hormonal pathways [7]. This study addresses the misconception that RMR is unaffected by energy availability; it examines how LEA alters resting metabolism as an energy-saving adaptation.

Physical Exercise on Metabolic Health in Obese Breast Cancer Survivors

A clinical trial is evaluating whether a 3-month dance-based exercise program combined with individualized nutrition can improve health outcomes in obese breast cancer survivors in remission [5]. The main questions it aims to answer are: Will the intervention reduce body weight, body fat, and visceral adiposity? Will it improve cardiorespiratory fitness, motor performance, gut microbiota composition, and quality of life? Researchers will compare women participating in the dance and nutrition program with a control group who maintain their usual lifestyle to see if the intervention leads to favorable metabolic, physical, and microbiome-related changes [5]. This study challenges the misconception that RMR is solely determined by genetics; it investigates whether lifestyle interventions can modify resting metabolism in a specific population.

Tirzepatide Impact Assessment Study

This study examines how two different weight-loss strategies affect heart and metabolic health, as well as changes at the molecular level in the body. One group includes adults who are starting a GLP-1 receptor agonist medication (i.e., semaglutide or tirzepatide) prescribed by their own doctor for weight loss. The other group includes adults who will participate in a structured lifestyle program combining a reduced-calorie diet with increased physical activity. Both groups complete assessments at the start of the study and again after three months. At each visit, participants have their weight, body composition, blood pressure, and resting metabolic rate measured [6]. This study addresses the misconception that all weight-loss strategies affect RMR equally; it compares pharmacological and lifestyle interventions.

Discovering Determinants of Food Intake by Application of Artificial Intelligence

Many people in the United States are overweight or obese. Researchers want to learn why some people can overeat and not gain weight, whereas others who do not overeat still gain weight [2]. The objective is to study factors related to food intake that can lead to weight gain over time. Eligibility includes healthy adults aged 18 to 60 years. Participants will have 6 to 8 clinic visits over 2 years. Procedures during visits may include collection of blood, hair, urine, and stool samples; measurement of the waist, neck, thighs, and other parts of the body; and dual energy x-ray absorption (DXA) scan [2]. This study challenges the misconception that RMR is the sole determinant of weight gain; it investigates complex, high-dimensional factors influencing energy balance.

GLP-1 Receptor Agonists and Energy Expenditure

A scoping review reports that weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat-free mass and fat mass losses) and mass-independent adaptations in EE (e.g., hormones). Glucagon-like peptide-1 receptor agonists (GLP-1RA) are indicated for obesity management; however, their effects on energy expenditure are not fully characterized [10]. This review addresses the misconception that RMR reduction during weight loss is purely a function of lost mass; it highlights mass-independent adaptations that may influence resting metabolism.

ROS-Driven Mitochondrial and mtDNA Release in Diabetes

Mitochondrial dysfunction driven by chronic hyperglycemia is a hallmark of diabetes, yet how this metabolic stress communicates pathological signals beyond individual cells remains poorly understood. A study identified a novel mechanism linking chronic hyperglycemia to systemic metabolic impairment through reactive oxygen species (ROS)-driven mitochondrial and mtDNA release [9]. This finding supports the understanding that RMR is influenced by cellular and systemic metabolic injury, challenging the misconception that RMR is independent of underlying disease processes.

If you are reading this for personal health reasons

The materials and compounds discussed on this page are sold for laboratory research use only. We do not provide dosing, medical guidance, or personal health advice. Anyone considering a compound for themselves should speak to a licensed clinician.